Prevention of pristane-induced arthritis by the oral administration of type II collagen

This is the first demonstration of a role for type II collagen in pristane-induced arthritis. Pretreatment with soluble type II collagen either lowers or raises the subsequent incidence and severity of pristane-induced arthritis. These effects are dependent upon both the dose and route of administra...

Full description

Saved in:
Bibliographic Details
Published in:Immunology 1993-05, Vol.79 (1), p.152-157
Main Authors: THOMPSON, S. J, THOMPSON, H. S. G, HARPER, N, DAY, M. J, COAD, A. J, ELSON, C. J, STAINES, N. A
Format: Article
Language:English
Subjects:
Administration, Oral
Animals
Arthritis - chemically induced
Arthritis - immunology
Arthritis - pathology
Biological and medical sciences
Collagen - administration & dosage
Collagen - pharmacology
Diseases of the osteoarticular system
Immunity, Cellular
Immunoglobulin G - biosynthesis
Injections, Intraperitoneal
Knee Joint - pathology
Male
Medical sciences
Mice
Mice, Inbred CBA
Miscellaneous. Osteoarticular involvement in other diseases
Terpenes
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This is the first demonstration of a role for type II collagen in pristane-induced arthritis. Pretreatment with soluble type II collagen either lowers or raises the subsequent incidence and severity of pristane-induced arthritis. These effects are dependent upon both the dose and route of administration of the soluble type II collagen. Increasing doses of orally administered type II collagen lowered both the incidence and severity of pristane-induced arthritis. Conversely, increasing doses of intraperitoneally administered type II collagen increased both the incidence and severity of arthritis. This exacerbation of pristane-induced arthritis was accompanied by elevated B- and T-cell responses to type II collagen. These findings highlight the importance of the site at which antigen is encountered in influencing subsequent immune responses and extend the observations of the use of orally administered antigens to ameliorate experimental autoimmunity.
ISSN:0019-2805
1365-2567